Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vidya Perera

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|September 10, 2020
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa InhibitionMohammed N Meah, Jennifer Raftis, Simon J Wilson, et al.
Clinical and Translational Science|October 25, 2024
Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approachPraneeth Jarugula, Sharif Soleman, Hyunmoon Back, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2024
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titrationPeter Chang, Vidya Perera, David H Salinger, et al.
Dermatology and Therapy|September 4, 2025
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized StudyStefan J Jodl, Margitta Worm, Frauke Friedrichs, et al.
Clinical Pharmacokinetics|February 9, 2020
Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical OutcomesBenjamin D W Harris, Viet Phan, Vidya Perera, et al.
Clinical Pharmacology and Therapeutics|April 30, 2025
Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With AsparaginasePraneeth Jarugula, Toni Ajavon-Hartmann, Obinna Obianom, et al.
International Journal of Antimicrobial Agents|January 3, 2015
Murine pharmacokinetics of rifapentine delivered as an inhalable dry powderJohn G Y Chan, Anneliese S Tyne, Angel Pang, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 StudyPaul Emery, Roy Fleischmann, Robert Wong, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart DiseaseAntoinette Ajavon-Hartmann, Praneeth Jarugula, Hyunmoon Back, et al.
British Journal of Clinical Pharmacology|January 19, 2018
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjectsVidya Perera, Joseph M Luettgen, Zhaoqing Wang, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Arteriosclerosis, Thrombosis, and Vascular Biology|September 10, 2020
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa InhibitionMohammed N Meah, Jennifer Raftis, Simon J Wilson, et al.
Clinical and Translational Science|October 25, 2024
Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approachPraneeth Jarugula, Sharif Soleman, Hyunmoon Back, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2024
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titrationPeter Chang, Vidya Perera, David H Salinger, et al.
Dermatology and Therapy|September 4, 2025
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized StudyStefan J Jodl, Margitta Worm, Frauke Friedrichs, et al.
Clinical Pharmacokinetics|February 9, 2020
Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical OutcomesBenjamin D W Harris, Viet Phan, Vidya Perera, et al.
Clinical Pharmacology and Therapeutics|April 30, 2025
Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With AsparaginasePraneeth Jarugula, Toni Ajavon-Hartmann, Obinna Obianom, et al.
International Journal of Antimicrobial Agents|January 3, 2015
Murine pharmacokinetics of rifapentine delivered as an inhalable dry powderJohn G Y Chan, Anneliese S Tyne, Angel Pang, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 StudyPaul Emery, Roy Fleischmann, Robert Wong, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart DiseaseAntoinette Ajavon-Hartmann, Praneeth Jarugula, Hyunmoon Back, et al.
British Journal of Clinical Pharmacology|January 19, 2018
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjectsVidya Perera, Joseph M Luettgen, Zhaoqing Wang, et al.
Pageof 5